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Background: Radiotherapy is a chosen treatment option for prostate cancer patients and while some tumours
respond well, up to 50% of patients may experience tumour recurrence. Identification of functionally relevant
predictive biomarkers for radioresponse in prostate cancer would enable radioresistant patients to be directed to
more appropriate treatment options, avoiding the side-effects of radiotherapy.
Methods: Using an in vitro model to screen for novel biomarkers of radioresistance, transcriptome analysis of a
radioresistant (PC-3) and radiosensitive (LNCaP) prostate cancer cell line was performed. Following pathway analysis
candidate genes were validated using qRT-PCR. The DNA repair pathway in radioresistant PC-3 cells was then
targeted for radiation sensitization using the PARP inhibitor, niacinimide.
Results: Opposing regulation of a DNA repair and replication pathway was observed between PC-3 and LNCaP cells
from RNA-seq analysis. Candidate genes BRCA1, RAD51, FANCG, MCM7, CDC6 and ORC1 were identified as being
significantly differentially regulated post-irradiation. qRT-PCR validation confirmed BRCA1, RAD51 and FANCG as
being significantly differentially regulated at 24 hours post radiotherapy (p-value =0.003, 0.045 and 0.003
respectively). While the radiosensitive LNCaP cells down-regulated BRCA1, FANCG and RAD51, the radioresistant
PC-3 cell line up-regulated these candidates to promote cell survival post-radiotherapy and a similar trend was
observed for MCM7, CDC6 and ORC1. Inhibition of DNA repair using niacinamide sensitised the radioresistant cells
to irradiation, reducing cell survival at 2 Gy from 66% to 44.3% (p-value =0.02).
Conclusions: These findings suggest that the DNA repair candidates identified via RNA-seq hold potential as both
targets for radiation sensitization and predictive biomarkers in prostate cancer.
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Radiation therapy (RT) is commonly used in the treat-
ment of prostate cancer. However, in many cases the
survival of cancer cells following RT can result in recur-
rence and disease progression. Current data indicates
that up to 50% of prostate cancer patients undergoing* Correspondence: khmoore@utas.edu.au
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unless otherwise stated.RT experience recurrence of the disease within 5 years
of treatment [1,2]. Regardless of tumour response to RT
patients may endure the side-effects, including radiation
proctitis, cystitis and erectile dysfunction (reviewed in
[3]). A personalised approach to treatment is urgently
needed allowing patients unlikely to benefit from con-
ventional RT to be directed towards hypofractionated
RT [4] or other therapeutic options.
Understanding the cellular factors contributing to resist-
ance to RT is vital in order to design tests to screen pa-
tients prior to receiving therapy and to develop adjuvantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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dictive biomarkers currently in use, for example EGFR
testing for treatment with tyrosine kinase inhibitors, rely
on the marker being functionally relevant, playing an inte-
gral role in therapeutic mechanism. While it has long been
known that RT operates by damaging DNA, to date there
are no clinically predictive markers available to indicate
the likelihood of an effective treatment outcome. It is con-
ceivable that tumours which behave in a similar way in
response to RT share similar features which can be used
as predictive biomarkers and this hypothesis is currently
under study for a range of cancers [5,6]. Prostate cancer
currently lacks predictive biomarkers for treatment
response and disease progression which are utilised suc-
cessfully within other malignancies [7,8]. Clinicopatho-
logic factors and prostate-specific antigen (PSA) levels
currently aid decision making when selecting treatment
for the individual patient however there is conflicting evi-
dence as to the predictive and prognostic value of these
markers [9-12]. While a number of markers have been
identified as prognostic or predictors of recurrence follow-
ing RT in prostate cancer [13-15] the studies published to
date have failed to reach clinical utility and do not con-
sider response to treatment.
In the search for a predictor of response, RNA sequen-
cing (RNA-seq) offers an unbiased screening approach
for potential novel biomarkers which relate to RT
response. This study compared the post-irradiation tran-
scriptome of a radiation resistant (PC-3) versus radio-
sensitive prostate cancer cell line (LNCaP). Previous
work has demonstrated that these two cell lines have op-
posing radiosensitivity [16-18] however to date the tran-
scriptome of these cell lines post-irradiation has not
been characterised. RNA-seq was used to gain a global
perspective of transcriptional changes to investigate the
factors integral in response to RT. From the variation in
transcriptional activity, specific pathways which relate to
differential response were revealed and validated by
qRT-PCR. A candidate pathway was selected and tar-
geted for inhibition to determine whether RT sensitisa-
tion was possible.Methods
Cell culture
The human prostate cancer LNCaP cell line (ATCC, USA)
was cultured in RPMI 1640, while PC-3 cells (ATCC, USA)
were grown in Ham’s F-12 K medium. Media was supple-
mented with 10% FBS and penicillin/streptomycin. For the
sensitisation experiments PC-3 cells were treated with
0.1 mM niacinimide (Sigma-Aldrich) for 24 hours prior to
and 8 days post-irradiation. This study does not use any hu-
man subjects or human material other than continuous cell
lines.Irradiation set-up
Radiotherapy treatment of prostate cancer cell lines was
carried out at the Holman Clinic at the Royal Hobart Hos-
pital, Tasmania, Australia. Irradiation was performed using
the Varian® Clinac® 23Ex Linear Accelerator (Varian Med-
ical Systems, Australia) which delivered doses between 2
and 8 Gray (Gy) at 600 monitor units (MU)/min.
Clonogenic cell survival assays
Prostate cancer cell lines were seeded at 1 × 103 cells/well
(PC-3) or 3 × 103 cells/well (LNCaP) and irradiated at 0, 2,
4 or 8 Gy. After 14 days of colony growth, medium was re-
moved and cells washed once in 1 ml of PBS. Colonies were
fixed with 700 μL of 3:1 methanol to glacial acetic acid for
5 minutes. Fixative agent was removed and wells air-dried
completely prior to staining. Cells were stained for 30 mi-
nutes in 500 μL of 1.0% methylene blue (Sigma-Aldrich,
USA) in 50% ethanol. Colonies were counted when prolif-
eration from a single viable cell exceeded 50 cells within
the colony. Percentage cell survival was determined as the
number of colonies post-treatment relative to the number
of colonies within the corresponding 0 Gy control.
RNA isolation
RNA was extracted using TRI reagent® (Sigma-Aldrich,
USA). For samples undergoing RNA-seq analysis RNA was
subjected to further purification including DNase treatment
for 15 minutes at room temperature and a second purifica-
tion step utilising the RNeasy Plus Micro Kit (Qiagen,
USA).
RNA-seq
RNA integrity was confirmed using the Agilent 2100 Bioa-
nalyser (Agilent Technologies, USA). Next-generation
sequencing was performed at the Australian Genome Re-
search Facility (AGRF) using the Illumina Hiseq-2000
RNA-seq sequence production system (50 cycle, single
end). Sequences were assessed for quality and then aligned
against the human genome using the Tophat aligner
(http://tophat.cbcb.umd.edu/). Comparison between the 0,
6 and 24 hour timepoints was performed using Cuffdiff
(http://cufflinks.cbcb.umd.edu/).
Ingenuity pathway analysis
The Ingenuity Pathway Analysis (IPA) program (https://
analysis.ingenuity.com/) was utilised to perform a core
analysis on the dataset gene files generated by RNA-seq.
The gene ID, fold change (>2) and q-value (<0.05) were
used for further analysis. Raw data was analyzed using the
flexible format and genes identified through human gene
symbols in association with the HUGO Gene Nomencla-
ture Committee (HGNC) and Entrez Gene guidelines.
Direct and indirect relationships between significant genes
were considered.
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Following irradiation RNA was isolated at specific time-
points and reverse transcribed to cDNA using Superscript
II reverse transcriptase (Invitrogen, USA). SYBR Green
PCR amplification was performed on the Rotor-Gene 2000
real-time cycler (Corbett Research, Australia) using Quanti-
tect SYBR Green PCR mastermix (Qiagen, Germany) ac-
cording to the manufacturer’s instructions in a total volume
of 10 μl, containing 20 ng of cDNA. Cycling conditions
were as follows: 95°C for 15 min; 95°C for 15 s, 60°C for
60 s for 35 cycles, followed by melt analysis from 60 to
95°C. Primers are listed in Table 1. Expression levels were
normalised to the house-keeping gene GAPDH.
Statistical analysis
Statistical analysis and graph generation was performed in
GraphPad Prism version 6.0d for Mac OSX, GraphPad
Software, La Jolla California USA, www.graphpad.com.
The clonogenic assay and gene expression assays were an-
alyzed using repeated measures two-way ANOVA. Cell
survival in response to niacinamide exposure was analyzed
using repeated measures one-way ANOVA. Cell survival
in response to niacinamide and radiation exposure was
analyzed using repeated measures two-way ANOVA. The
Sídák multiple comparison test was used following each
analysis.
Western blotting
Nuclear extracts were prepared as previously described
[19]. Protein concentrations were determined by Bradford
Assay (Bio-Rad, USA). Protein extracts were run on a 12%
Mini-PROTEAN® TGX™ pre-cast gel (Bio-Rad, USA) and
transferred onto nitrocellulose membrane. Western-blot















GAPDH Rev 5′-AGCCCAGGATGCCCTTGAGGG-3′and anti-Sp1 antibodies (Santa Cruz Biotechnology, USA)
and the corresponding peroxidase-conjugated secondary
antibodies (DAKO, Denmark). Proteins were visualized
using the Supersignal West Pico Chemiluminescent kit
(Pierce ThermoScientific, USA) according to the manufac-
turer’s instructions.
Results
Clonogenic cell survival post-irradiation demonstrates a
significant difference between LNCaP and PC-3 cells
LNCaP and PC-3 cells, isolated from prostate cancer
lymph and bone metastases respectively, have previously
been used as models for radiation sensitivity [17,18]. In
order to confirm these cells behaved as per the literature
in our irradiation set-up, the radiation sensitivity of these
prostate cancer cell lines was confirmed via clonogenic
assay following irradiation. In both cell lines decreased
levels of survival were observed with increasing irradi-
ation dose. The PC-3 cell line showed the greatest level
of resistance to radiotherapy following 2 Gy irradiation
with over 73% cell survival (Figure 1). In contrast, only
36% cell survival was measured for the LNCaP cell line
indicating their increased sensitivity (p-value 0.002). In
both cell lines less than 10% of cells were able to gener-
ate viable colonies following 4 Gy irradiation and less
than 1% cell survival was observed after 8 Gy irradiation.
Pathway analysis demonstrates DNA repair and
replication were significantly upregulated in the
radioresistant cells and downregulated in the
radiosensitive cells
To identify differences in genes and pathways affected
by irradiation, RNA-seq was performed on the LNCaP
and PC-3 cells. Following 2 Gy irradiation (equivalent to
the fractionated irradiation dosage commonly received
by patients) RNA was isolated at 0, 6 and 24 hours prior
to sequencing via the Illumina Hiseq-2000 RNA-seq
platform.
The gene lists generated for radiosensitive LNCaP and
radioresistant PC-3 cells at 6 and 24 hours following 2 Gy
irradiation showed large differences in both the number
and type of genes that were transcriptionally activated. Ir-
radiation appeared to impact transcriptional response to a
greater extent within the PC-3 cell line with 399 genes sig-
nificantly differentially regulated by 6 hours (using a 2 fold
cut-off). In comparison, at the same time-point only 89
genes were significantly up- or down-regulated for the ra-
diosensitive LNCaP cell line. An unbiased analysis of the
gene lists obtained from RNA-seq was then used to un-
cover pathways involved in radioresponse. Interactions be-
tween significantly differentially regulated genes in each
cell line were determined using Ingenuity Pathway Ana-
lysis (IPA). Two canonical pathways identified were shown
to have opposing responses 24 hours after irradiation. The

















Figure 1 PC-3 and LNCaP cell survival following irradiation. Clonogenic assays were carried out to establish difference in cell survival
between the two cell lines following radiotherapy treatment at 0, 2, 4 and 8 Gy. Percentage cell survival at each irradiation dose was determined
as the proportion of colonies present after treatment (2, 4 and 8 Gy) in comparison to colony numbers within the untreated control sample at
0 Gy. The mean and SEM from three biological replicates are shown, p-value determined by two way ANOVA and Sidak’s post test.
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cell lines was a DNA repair pathway. While key genes
within this pathway were significantly up-regulated in the
radioresistant PC-3 cell line (Figure 2A) the same subset
of genes were oppositely regulated, displaying down-
regulation within the radiosensitive LNCaP cell line
(Figure 2B). These oppositely regulated genes include
BRCA1, RAD51 and FANCG.
The cell cycle control of DNA replication pathway was
also observed as the other top canonical pathway af-
fected by irradiation in the cell lines (Additional file 1:
Figure S1). Up-regulation of ORC1, CDC6 and the
MCM genes was observed at 6 and 24 hours after irradi-
ation in PC-3 cells. In contrast, the LNCaP cell line
showed significant down-regulation of the equivalent
subset of genes at 24 hours.
Another potential way to find a predictive biomarker
is to screen for genes with strong basal expression. The
top 10 genes identifiable by RNA-seq were filtered and
are listed in Additional file 2: Table S1 along with the
contrasting value in the alternate cell line. While these
genes may prove to be relevant predictors, a predictive
biomarker is more robust when it is functionally rele-
vant. Therefore the focus of this study remained on the
genes involved in the two key pathways responsible for
differential radiation response.
BRCA1, RAD51 and FANCG mRNA display significant
opposing regulation in response to radiotherapy in the
radiosensitive versus radioresistant cells
In order to validate the candidate genes identified by RNA-
seq, expression levels following 2 Gy irradiation wereassessed using qRT-PCR. The LNCaP cell line demon-
strated a slight increase in BRCA1 expression at 6 hours
post RT followed by down-regulation within 24 hours post
RT to 0.2 fold of the basal level. In contrast BRCA1
mRNA was up-regulated in PC-3 cells post-irradiation to
1.5 fold by 24 hours. Comparison of BRCA1 expression in
the LNCaP and PC-3 cell line at 24 hours confirmed op-
posing regulation with a significant difference observed
(p-value 0.003).
FANCG mRNA also displayed significant opposing
regulation at 24 hours post RT being down-regulated by
0.4 fold in the LNCaP cells and up-regulated by 1.5 fold
in the PC-3 cells (p-value 0.003, Figure 3B).
RAD51 mRNA levels decreased by 0.4 fold basal levels
at 24 hours in the LNCaP cells (Figure 3C). In contrast,
RAD51 expression was up-regulated in the PC-3 cells by
1.8 and 2.6 fold at 6 and 24 hours post RT respectively.
This difference in RAD51 mRNA expression between the
two cell lines at 24 hours was shown to be significant
(p-value 0.045). The DNA replication candidates MCM7,
ORC1 and CDC6 mRNA levels displayed a similar trend
with down-regulation in the LNCaP cells and up-regulation
in the PC-3 cells at 24 hours (Figure 3D-F). However, this
difference was found to be non significant.
Nuclear levels of BRCA1 and RAD51 protein diminished in
the radiosensitive cells while increasing in the
radioresistant cells post-irradiation
BRCA1 and RAD51 protein expression was then examined
as these genes showed significant differential responses fol-
lowing radiation treatment and are directly involved in







Figure 2 (See legend on next page.)
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Figure 2 Pathway analysis highlights opposing regulation of a DNA repair pathway in radioresistant versus radiosensitive cells. Gene lists
determined by RNA-seq for the (A) PC-3 and (B) LNCaP cell lines 24 hours after 2 Gy irradiation were analysed using IPA. DNA repair pathways were
identified as being significantly altered in response to RT (q-value 1x10−10). Significantly up-regulated genes are coloured red and down-regulated
green, those present within our data set but not significant are shown in grey. Significant genes were defined as reporting a log2 fold change >1 and
a q-value <0.05. Arrows indicate gene products which were found to be oppositely regulated.
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cells. Multiple BRCA1 isoforms were detected in the LNCaP
cell line at approximately 220 kDa, along with the highly
abundant 81 and 85 kDa isoforms (Figure 4). While the
levels of full length BRCA1 (220 kDa) remained relatively
stable across all time points, the smaller isoforms decreased
from 0 to 24 hours post RT. In the PC-3 cell line this lower
band was barely detectable at the 0 hour time-point but in-
creased at 24 hours and a similar trend was observed for the
full length BRCA1 protein. Another larger band was also de-
tected at 250 kDa being present in the irradiated and non-
irradiated PC-3 cells. This band was relatively consistent
across all treatment time-points for the PC-3 cells while it
was also faintly detected in irradiated LNCaP cells poten-
tially representing phosphorylated BRCA1.
Consistent with the differential transcriptional regula-
tion in the two cell lines (Figure 3C) RAD51 expression
decreased following RT in the LNCaP cells with a no-
ticeable reduction in expression at 24 hours. In contrast
up-regulation of RAD51 was observed at 6 hours post
RT in the PC-3 cell line, and appeared to remain greater
than the basal level at 24 hours post RT. The detection
of a strong, second band just below 34 kDa was ob-
served in the PC-3 cells at all time points. This second
band was confirmed to be a novel non-functional
RAD51 splice variant (Additional file 3 and Additional
file 4: Figure S2). The amplicon lacked the sequence cor-
responding to exon 9 of RAD51, a previously identified
sequence variant [20] however the variant sequenced
from the PC-3 cells was also missing 130 bp of the 3
prime end of exon 8. The predicted amino acid sequence
of the variant consists of codons 1 to 214 and 299 to
339 of full length RAD51. The translated protein con-
tains the Walker A ATP binding motif, but is lacking the
Walker B ATP binding motif.The PARP inhibitor niacinamide successfully sensitised
radioresistant prostate cancer cells to irradiation
Poly ADP-ribose polymerase (PARP) inhibitors have
previously been shown to inhibit DNA repair and
down-regulate BRCA1 and RAD51 [21]. To determine
whether radioresistant cells could be rendered sensitive
by targeting the DNA repair pathway, the PARP inhibi-
tor niacinamide was added to cells prior to irradiation.
Prior to sensitisation assays the toxicity of niacinamide
was determined and the optimal concentration selectedas a low and clinically relevant dosage without a signifi-
cant effect on cell survival (Figure 5A).
Cells were treated with 0.1 mM niacinimide for 24 hours
prior to irradiation and 8 days post-irradiation. Cells were
irradiated at 0, 2, 4 and 8 Gy and survival assessed via clo-
nogenic assay. As shown in Figure 5B, for untreated PC-3
cells approximately 66% cell survival was measured fol-
lowing 2 Gy irradiation. Treatment of cells with niacin-
amide significantly reduced cell survival to 44.3% (p-value
0.02). This result was reiterated at 4 Gy with 18% of un-
treated cells surviving in contrast to cells sensitised with
niacinamide exhibiting only 9% cell survival (Figure 5B).
Following 8 Gy irradiation in untreated cells, 7% cell sur-
vival was observed while in contrast no formation of vi-
able colonies within the niacinamide-treated PC-3 cells
was apparent.
Discussion
The genetic heterogeneity observed in prostate cancer
results in tumours from different individuals displaying
significant variation in response to treatment [22,23].
Understanding the molecular pathology that contributes
to this variation will enable tailoring treatment to spe-
cific tumour subtypes [24,25]. In order to gain insight
into the molecular mechanism underpinning radiation
sensitivity an unbiased approach was employed to iden-
tify differential gene expression relating to radiore-
sponse. It has long been known that ionising radiation
induces several forms of DNA damage [26,27] therefore,
it was not surprising that the two most significant path-
ways observed to be altered following irradiation relate
functionally to DNA repair and replication. In a previ-
ously unreported finding, these pathways were shown to
be oppositely regulated in the radioresistant PC-3 cell
line versus the radiosensitive LNCaP cell line. The radio-
resistant cells, by actively up-regulating genes in these
pathways promoted cell survival. In contrast the radio-
sensitive cells inhibit expression of these very same
genes, leading to cell death. The time taken to initiate
DNA repair following irradiation has been previously
identified as a major factor in determining radioresponse
[28-30]. Identifying the level of response of these genes
during the initial acute phase following irradiation may
indicate the level of radiosensitivity.
The regulation of DNA repair and replication genes
BRCA1, RAD51, FANCG, ORC1, CDC6 and MCM7 cor-









































































































































































Figure 3 Regulation of candidate gene expression in response to radiotherapy in LNCaP and PC-3 cell lines. Cells were exposed to 2 Gy
irradiation and RNA was extracted at 0 (non-irradiated) 6 and 24 hours post RT. cDNA was amplified via real-time PCR using primers designed
against (A) BRCA1, (B) FANCG, (C) RAD51, (D) ORC1, (E) MCM7, (F) CDC6 and expression levels normalised qRT-PCR to GAPDH. Fold change was
calculated relative to the non-irradiated control. Error bars represent standard error of the mean from 3 biological replicates, p-values determined
by two way ANOVA and Sidak’s post test.
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Figure 4 Nuclear expression of BRCA1 and RAD51 following
irradiation in the LNCaP and PC-3 cell lines. Nuclear proteins
were extracted from cells at 0 (non-irradiated), 6 and 24 hours
following exposure to 2 Gy irradiation. Protein expression was
analysed via Western blot. HeLa nuclear protein extract was utilised
as a positive control and membranes were probed for Sp1 as a
loading control.
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ously been linked to various treatment responses in a
number of cancers [31-33] limited research exists investi-
gating the association between RT-induced regulation of
these genes in radiation resistant prostate cancer. These
genes appear to be key in regulating radiation response
and therefore these pathways or their upstream regulators
may prove to be a good predictor of treatment outcome.
The DNA replication genes identified via RNA-seq war-
rant further investigation, while a trend was confirmed by
qRT-PCR this was not significant. Future work in further
characterising several of the candidates in patient biopsies
is needed. With further investigation variants or basal pat-
terns may prove to be predictive of response.
BRCA1 expression was found to have a strong association
with radiation response, with significant opposing regulation
observed between the two cell lines. BRCA1 has been iden-
tified as a primary regulator of the repair of DNA double-
stranded breaks (DSB), which are formed on exposure to
ionising radiation (reviewed in [34]). BRCA1 mutation and
exogenous down-regulation has also previously been found
to increase sensitivity to RT in a variety of cancer cell lines
[35,36] however no evidence is available for prostate cancer
cells. The novel finding that prostate cancer cells with dis-
parate radiosensitivity exhibit opposing regulation of BRCA1
following RT supports its involvement in determining radi-
ation response. Interestingly, the initial RNA-seq analysis
demonstrated that a key transcription factor in BRCA1
regulation, E2F1 [37,38] was significantly down-regulated in
the LNCaP cell line at 24 hours post-RT, which may explain
the decrease in BRCA1 expression at the same time point.
This transcription factor is also involved in regulating
RAD51 and CDC6 expression [39,40]. In terms of potential
implications for this finding it is unlikely that basal BRCA1
mRNA levels could be used as a predictive biomarker.
While post RT levels of BRCA1 are more informative, it isunlikely patient biopsies could be taken at this point. Re-
gardless, BRCA1 is an appealing target for sensitisation and
screening BRCA1 mutations may help direct patients to
their most optimal treatment.
It should also be noted that, as is the case in patient tu-
mours, the LNCaP and PC-3 cell lines have many inherent
differences. For example LNCaP cells are androgen sensitive
and p53 positive [41,42] while the PC-3 cells are androgen
resistant and p53 null [42,43]. Regardless, p53 was not iden-
tified as being significantly differentially regulated in the p53
positive cell line post RT. Previous research has investigated
p53 status as a predictive biomarker for radiation response
in prostate cancer however, the large range of possible p53
mutations has led to conflicting results. Whilst some studies
found that resistant tumours had a higher level of expression
[44,45] others concluded that p53 expression was compar-
able in both radiation sensitive and radiation resistant tu-
mours [46,47]. Therefore, investigations into p53 targets,
such as BRCA1 and RAD51, as predictors may be a more
promising avenue for future research.
Radiation sensitisation strategies have been successful in
the treatment of a variety of cancers [48-51] however clin-
ically effective strategies have remained elusive in prostate
cancer. This study demonstrated the efficacy of PARP in-
hibition in sensitising the radiation resistant PC-3 prostate
cancer cell line to the effects of RT. Niacinamide is a
known inhibitor of PARPs which are involved in the repair
of single-stranded breaks (SSB) [52]. All PARP inhibitors
are based on the structure of niacinamide and use the
same competitive binding strategy [53]. Importantly,
PARP inhibition has also previously been demonstrated to
down-regulate BRCA1 and RAD51 [21]. Much of the
current research surrounds the use of PARP inhibitors as
effective mono-therapy for breast and ovarian cancers
with BRCA1 and BRCA2 mutations [54-56]. However, evi-
dence for their radiation sensitisation capabilities is emer-
ging from in vivo studies [57]. The use of niacinamide as a
sensitisation strategy is an appealing possibility, due to the
fact this compound has FDA approval and has beneficial
effects (reviewed in [58]).
RAD51 is another promising target to enhance response
to RT as clinically approved inhibitors are already available.
RAD51 has previously been proposed as a possible target
for radiosensitisation through inhibition using imatinib in
prostate cancer xenografts [59]. Recent evidence demon-
strates that imatinib down-regulates RAD51 expression and
sensitises bladder and glioma cancer cells to RT [60,61].
Further molecular characterisation of the precise involve-
ment of BRCA1 and RAD51 may contribute to more tar-
geted radiosensitisation strategies.
Conclusions
This study is the first to characterise the post irradiation
transcriptome of two prostate cancer cell lines with







































Figure 5 Adjuvant treatment with niacinamide significantly increases the radiation response of PC-3 cells. A) PC3 cells were incubated with
varying concentrations of the PARP inhibitor niacinamide for 8 days and cell colonies of greater than 50 cells were counted. Cell survival percentages were
calculated relative to the number of colonies counted in the untreated population. Error bars represent standard error of the mean from 3 biological
replicates. p-values determined by one way ANOVA. B) PC-3 cells were incubated with or without niacinamide for 24 hours prior to and 8 days following
exposure to 0, 2, 4 or 8 Gy irradiation. Following incubation, colonies of greater than 50 cells were counted, and cell survival percentages were calculated
relative to the appropriate non-irradiated colony counts. Error bars represent standard error of the mean from 3 biological replicates. p-values as
determined by two way ANOVA and Sidak’s post test.
Young et al. BMC Cancer 2014, 14:808 Page 9 of 12
http://www.biomedcentral.com/1471-2407/14/808divergent responses to RT commonly used in research.
RNA-seq analysis revealed the potential for BRCA1 and
RAD51 as biomarkers for radiation response. RT-induced
regulation of both transcription and nuclear protein local-
isation was found to be associated with the differential radi-
ation response of LNCaP and PC-3 prostate cancer cell
lines. Given the role of BRCA1 and RAD51 in the homolo-
gous repair of DSBs, it is likely that their increased expres-
sion contributes to the repair of the DNA damage caused
by RT to promote survival in resistant cells. In addition,PARP has been identified as a putative target for adjuvant
sensitisation strategies.
Translational research has an overall aim to be used clin-
ically, providing benefits for patients, therefore the ability to
validate in vitro based markers in vivo will be essential.
Analysis of the behaviour of prostate cancer cell lines pro-
vides a reference point for possible traits that cause RT
resistance. Importantly, the data generated by RNA-seq has
provided potential leads on influential pathways, which are
affected by irradiation. In addition, inhibition of gene
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prostate cancer cells to cell death following RT. Additional
validation of these targets using patient biopsies will be im-
perative to understanding their potential clinical utility.
Similarly, sensitisation agents require validation in mouse
models (such as TRAMP and PTEN-induced prostate-
specific cancer formation PTENfl/fl; probasin-Cre mice)
prior to determining their suitability for clinical trials. Prov-
ing candidate markers and sensitisation agents to be clinic-
ally significant remains a definite challenge. However, with
improving technology to recognise molecular subtleties
which separate particular treatment responses, new oppor-
tunities for tailoring therapeutics will become available.
This will enable increased translational research into the
individualised management of prostate cancer patients pro-
viding advantages to the overall survival benefit received by
patients. As niacinamide is a safe, well tolerated FDA ap-
proved vitamin supplement, its sensitisation effects could
also be investigated by surveying patients taking such sup-
plements followed by correlation with response data. Fi-
nally, the biomarkers and sensitisation strategy identified in
this study may not only prove to be effective in prostate tu-
mours, but may be relevant to numerous cancer types as a
mechanism for inherent radiation resistance.Additional files
Additional file 1: Figure S1. Differential regulation of cell cycle control
of chromosomal replication pathway in PC-3 and LNCaP cells. IPA was
performed on gene lists generated by RNA-seq of the A) PC-3 and B)
LNCaP cell lines 24 hours following 2 Gy irradiation. The DNA replication
pathway was identified as being significantly altered in response to RT
(q-value 5x10−8). Significantly up-regulated genes are coloured red and
down-regulated green, genes that showed differential expression at
non-significant levels are shown in grey. Significant genes were defined
as reporting a log2 fold change >1 and a q-value <0.05.
Additional file 2: Table S1. Top 10 known genes with highest basal
expression in the LNCaP versus PC-3 cells.
Additional file 3: Additional methods.
Additional file 4: Figure S2. Alignment of the amino acid sequences
of RAD51 and a novel RAD51 variant. PCR was performed utilising
primers designed to amplify full length RAD51 and a previously identified
variant, RAD51Δ ex9. The smaller PCR product was extracted from the gel
and sequenced. The resultant sequence was translated into the predicted
amino acid sequence of the amplicon and aligned with the amino acid
sequence of full length RAD51. Grey shading represents amino acids that
are missing from the novel variant. Arrows indicate exons 8, 9 and 10.
The Walker A ATP binding motif is indicated by the black box, whilst the
Walker B ATP binding motif is indicated in bold type and underlined.
*represents a stop codon.Abbreviations
DSB: Double stranded break; Gy: Gray; IPA: Ingenuity pathway analysis;
PARP: Poly ADP ribose polymerase; qRT-PCR: Quantitative reverse
transcription polymerase chain reaction; RNA-seq: RNA sequencing;
RT: Radiation therapy; SSB: Single stranded break.
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